Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Recruiting
NCT06285643Phase 2Updated Jun 29, 2026
Sponsor: AskBio Inc
Parkinson Disease
United States, Germany, Poland, United Kingdom
Effects of Osteopathic Manipulative Treatment Protocol on Sleep Quality in Parkinson's Disease SubjectsRecruiting
NCT06671600NAUpdated Jun 29, 2026
Sponsor: New York Institute of Technology
Parkinsons Disease · Sleep
United States
Outlining Biological Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease Patients.Not Yet Recruiting
NCT07673783N/AUpdated Jun 29, 2026
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Parkinson Disease (PD)
Exercise for Cognitive Excellence in Parkinson's DiseaseCompleted
NCT05720468NAUpdated Jun 29, 2026
Sponsor: University of California, San Francisco
Parkinson Disease
United States
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Recruiting
NCT06788912Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
United States, Chile, Greece, Hungary, Italy +4 more
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)Completed
NCT04738487Phase 3Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasms · Non-Small-Cell Lung Carcinoma
United States, Brazil, Canada, Chile, China +18 more
rTMS and Olfactory Training for Parkinson's DiseaseCompleted
NCT07666477NAUpdated Jun 26, 2026
Sponsor: Mustafa Baran
Parkinson Disease (PD) · Olfactory Dysfunction
Turkey (Türkiye)
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)Completed
NCT04165096Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +2 more
Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current StimulationNot Yet Recruiting
NCT07534397NAUpdated Jun 26, 2026
Sponsor: The University of Texas at Dallas
PARKINSON DISEASE (Disorder)
United States
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China StudyRecruiting
NCT07216976NAUpdated Jun 26, 2026
Sponsor: MedtronicNeuro
Parkinson's Disease
China
Neurologic Stem Cell Treatment StudyRecruiting
NCT02795052NAUpdated Jun 26, 2026
Sponsor: MD Stem Cells
Neurologic Disorders · Nervous System Diseases · Neurodegenerative Diseases · Neurological Disorders
United States, United Arab Emirates
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)Active Not Recruiting
NCT05298423Phase 3Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Brazil, Chile +20 more
Virtual Reality Verses Conventional Physical Therapy in Parkinson's Disease PatientsCompleted
NCT07359716NAUpdated Jun 26, 2026
Sponsor: Montiha Azeem
Parkinson s Disease
Pakistan
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting
NCT05319730Phase 1, Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Germany +9 more
Natural History Protocol for Movement DisordersRecruiting
NCT05413291N/AUpdated Jun 25, 2026
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Movement Disorder · Tremor · Parkinson's Disease
United States
Trial of Parkinson's And Zoledronic AcidCompleted
NCT03924414Phase 4Updated Jun 25, 2026
Sponsor: California Pacific Medical Center Research Institute
Parkinson Disease · Osteoporosis · Parkinsonism · Parkinson's Disease and Parkinsonism
United States
The French E3N Prospective Cohort StudyActive Not Recruiting
NCT03285230N/AUpdated Jun 25, 2026
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Breast Cancer · Colo-rectal Cancer · Parkinson Disease · Asthma
France
Targeted Motor Learning to Improve Gait for Individuals With Parkinson DiseaseRecruiting
NCT05864157NAUpdated Jun 25, 2026
Sponsor: University of North Carolina, Chapel Hill
Parkinson Disease
United States
Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs. Dual TaskNot Yet Recruiting
NCT07660978NAUpdated Jun 25, 2026
Sponsor: Bezmialem Vakif University
PARKINSON DISEASE (Disorder) · Parkinson Disease (PD) · Parkinson s Disease · Postural Instability
Sustained Release Oral Formulation for Treatment of Parkinson's DiseaseCompleted
NCT05471609EARLY_Phase 1Updated Jun 25, 2026
Sponsor: University of Minnesota
Healthy Volunteers
United States
IMPACT 360 for Parkinson's DiseaseActive Not Recruiting
NCT07443293Phase 2Updated Jun 25, 2026
Sponsor: University of British Columbia
Parkinson's Disease (PD) · REM Sleep Behavior Disorder
Canada
Subthalamic Nucleus Stimulation With Directional Leads on Patients With Parkinson Disease at Fluctuations and Dyskinesia StageCompleted
NCT05103072N/AUpdated Jun 24, 2026
Sponsor: Centre Hospitalier Universitaire, Amiens
Parkinson Disease · Subthalamic Nucleus Stimulation · Directional Electrodes
France
Temporal Interference Stimulation on Motor Symptoms in Parkinson's DiseaseCompleted
NCT07309198NAUpdated Jun 24, 2026
Sponsor: Shanghai University of Sport
Parkinson's Disease
China
Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's DiseaseCompleted
NCT04002596NAUpdated Jun 24, 2026
Sponsor: InSightec
Parkinson Disease
China, Japan
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)Recruiting
NCT07666022Phase 1Updated Jun 24, 2026
Sponsor: University of Shizuoka
Healthy Adult Male · PARKINSON DISEASE (Disorder)
Japan

Previous page Next page